U.S. FTC Clears Mylan's Agila Acquisition If It Divests 11 Drugs
This article was originally published in PharmAsia News
Executive Summary
Mylan's $1.6 billion acquisition of Strides Arcolab's Agila unit has received the approval of the U.S. Federal Trade Commission, but only if it agrees to divest itself of several of its drugs.